Glenmark to launch higher strength of FabiFlu for treatment of mild to moderate Covid
[ad_1] Glenmark has also commenced a post-marketing surveillance study on FabiFlu to closely monitor the efficacy and safety of the drug in a large pool of patients prescribed with the oral antiviral Favipiravir, as part of an open label, multicenter, single arm study. [ad_2] Source link
Glenmark to launch higher strength of FabiFlu for treatment of mild to moderate Covid Read More »